Literature DB >> 20979234

Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10.

Karin Frank-Raue1, Lisa A Rybicki, Zoran Erlic, Heiko Schweizer, Aurelia Winter, Ioana Milos, Sergio P A Toledo, Rodrigo A Toledo, Marcos R Tavares, Maria Alevizaki, Caterina Mian, Heide Siggelkow, Michael Hüfner, Nelson Wohllk, Giuseppe Opocher, Sárka Dvořáková, Bela Bendlova, Małgorzata Czetwertynska, Elżbieta Skasko, Marta Barontini, Gabriela Sanso, Christian Vorländer, Ana Luiza Maia, Attila Patocs, Thera P Links, Jan Willem de Groot, Michiel N Kerstens, Gerlof D Valk, Konstanze Miehle, Thomas J Musholt, Josefina Biarnes, Svetozar Damjanovic, Mihaela Muresan, Christian Wüster, Martin Fassnacht, Mariola Peczkowska, Christine Fauth, Henriette Golcher, Martin A Walter, Josef Pichl, Friedhelm Raue, Charis Eng, Hartmut P H Neumann.   

Abstract

Multiple endocrine neoplasia type 2 is characterized by germline mutations in RET. For exon 10, comprehensive molecular and corresponding phenotypic data are scarce. The International RET Exon 10 Consortium, comprising 27 centers from 15 countries, analyzed patients with RET exon 10 mutations for clinical-risk profiles. Presentation, age-dependent penetrance, and stage at presentation of medullary thyroid carcinoma (MTC), pheochromocytoma, and hyperparathyroidism were studied. A total of 340 subjects from 103 families, age 4-86, were registered. There were 21 distinct single nucleotide germline mutations located in codons 609 (45 subjects), 611 (50), 618 (94), and 620 (151). MTC was present in 263 registrants, pheochromocytoma in 54, and hyperparathyroidism in 8 subjects. Of the patients with MTC, 53% were detected when asymptomatic, and among those with pheochromocytoma, 54%. Penetrance for MTC was 4% by age 10, 25% by 25, and 80% by 50. Codon-associated penetrance by age 50 ranged from 60% (codon 611) to 86% (620). More advanced stage and increasing risk of metastases correlated with mutation in codon position (609→620) near the juxtamembrane domain. Our data provide rigorous bases for timing of premorbid diagnosis and personalized treatment/prophylactic procedure decisions depending on specific RET exon 10 codons affected.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20979234     DOI: 10.1002/humu.21385

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  38 in total

Review 1.  Management of hereditary medullary thyroid carcinoma.

Authors:  Theodora Pappa; Maria Alevizaki
Journal:  Endocrine       Date:  2016-02-02       Impact factor: 3.633

Review 2.  Translational research in endocrine surgery.

Authors:  Scott K Sherman; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2013-07-26       Impact factor: 3.495

3.  Clinical utility gene card for: multiple endocrine neoplasia type 2.

Authors:  Friedhelm Raue; Susanne Rondot; Egbert Schulze; Sylwia Szpak-Ulczok; Barbara Jarzab; Karin Frank-Raue
Journal:  Eur J Hum Genet       Date:  2011-08-24       Impact factor: 4.246

4.  The RET C611Y mutation causes MEN 2A and associated cutaneous lichen amyloidosis.

Authors:  Xiao-Ping Qi; Jian-Zhong Peng; Xiao-Wei Yang; Zhi-Lie Cao; Xiu-Hua Yu; Xu-Dong Fang; Da-Hong Zhang; Jian-Qiang Zhao
Journal:  Endocr Connect       Date:  2018-07-26       Impact factor: 3.335

Review 5.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

Review 6.  RET revisited: expanding the oncogenic portfolio.

Authors:  Lois M Mulligan
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

Review 7.  Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood.

Authors:  Jonathan D Wasserman; Gail E Tomlinson; Harriet Druker; Junne Kamihara; Wendy K Kohlmann; Christian P Kratz; Katherine L Nathanson; Kristian W Pajtler; Andreu Parareda; Surya P Rednam; Lisa J States; Anita Villani; Michael F Walsh; Kristin Zelley; Joshua D Schiffman
Journal:  Clin Cancer Res       Date:  2017-07-01       Impact factor: 12.531

Review 8.  Management of medullary thyroid carcinoma and MEN2 syndromes in childhood.

Authors:  Steven G Waguespack; Thereasa A Rich; Nancy D Perrier; Camilo Jimenez; Gilbert J Cote
Journal:  Nat Rev Endocrinol       Date:  2011-08-23       Impact factor: 43.330

9.  Genetic diagnosis of a Chinese multiple endocrine neoplasia type 2A family through whole genome sequencing.

Authors:  Zhen-Fang DU; Peng-Fei Li; Jian-Qiang Zhao; Zhi-Lie Cao; Feng Li; Ju-Ming Ma; Xiao-Ping Qi
Journal:  J Biosci       Date:  2017-06       Impact factor: 1.826

Review 10.  Biologic and Clinical Perspectives on Thyroid Cancer.

Authors:  James A Fagin; Samuel A Wells
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.